ArticleInternational journal of women's health2025
Lymphadenectomy and Sentinel Lymph Node Biopsy in Patients with Endometrial Cancer in Intermediate and High-Intermediate Risk Groups: The Ukrainian Experience.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To analyze the oncological safety of sentinel lymph node biopsy compared to lymphadenectomy. Additionally, we evaluated the postoperative complications of the two methods. Patients and Methods: This retrospective multicenter trial included 118 patients with intermediate and high-intermediate Stage I-II endometrioid endometrial cancer. Patients with non-endometrioid tumors and those with lymphadenopathy detected on computed tomography were excluded. The study group underwent sentinel lymph node biopsy. In contrast, the control group underwent systematic lymphadenectomy up to the renal vessels, the level of the inferior mesenteric artery, or the bifurcation of the iliac vessels. Recurrence-free survival was calculated using the Kaplan-Meier method. Differences were considered statistically significant at p < 0.05 (95% confidence interval). Results: Patients were recruited from 2017 to March 2024. In the control group, six (5.9%) patients experienced disease recurrence and five (4.2%) died. Overall, two (1.7%) patients from both groups died from causes unrelated to recurrence. Recurrence-free survival did not significantly differ between those who underwent sentinel lymph node biopsy (96.3%, SE ± 0.036) and those who underwent lymphadenectomy (89.4%, SE ± 0.045) over 3 years from the date of surgery to the time of the first recurrence (p = 0.608). Eighteen postoperative complications were identified: 11 (9.3%) patients experienced complications within 30 days of follow-up, and 7 (5.9%) within 90 days. Conclusion: Sentinel lymph node biopsy may serve as an alternative to systemic lymphadenectomy for surgical staging without compromising recurrence-free survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.